{Reference Type}: Journal Article
{Title}: Ovarian Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology.
{Author}: Armstrong DK;Alvarez RD;Bakkum-Gamez JN;Barroilhet L;Behbakht K;Berchuck A;Chen LM;Cristea M;DeRosa M;Eisenhauer EL;Gershenson DM;Gray HJ;Grisham R;Hakam A;Jain A;Karam A;Konecny GE;Leath CA;Liu J;Mahdi H;Martin L;Matei D;McHale M;McLean K;Miller DS;O'Malley DM;Percac-Lima S;Ratner E;Remmenga SW;Vargas R;Werner TL;Zsiros E;Burns JL;Engh AM;
{Journal}: J Natl Compr Canc Netw
{Volume}: 19
{Issue}: 2
{Year}: 02 2021 2
{Factor}: 12.693
{DOI}: 10.6004/jnccn.2021.0007
{Abstract}: Epithelial ovarian cancer is the leading cause of death from gynecologic cancer in the United States and is the country's fifth most common cause of cancer mortality in women. A major challenge in treating ovarian cancer is that most patients have advanced disease at initial diagnosis. These NCCN Guidelines discuss cancers originating in the ovary, fallopian tube, or peritoneum, as these are all managed in a similar manner. Most of the recommendations are based on data from patients with the most common subtypes─high-grade serous and grade 2/3 endometrioid. The NCCN Guidelines also include recommendations specifically for patients with less common ovarian cancers, which in the guidelines include the following: carcinosarcoma, clear cell carcinoma, mucinous carcinoma, low-grade serous, grade 1 endometrioid, borderline epithelial, malignant sex cord-stromal, and malignant germ cell tumors. This manuscript focuses on certain aspects of primary treatment, including primary surgery, adjuvant therapy, and maintenance therapy options (including PARP inhibitors) after completion of first-line chemotherapy.